Abstract
Introduction and hypothesis
Current treatment modalities for anal sphincter injuries are ineffective for many patients, prompting research into restorative and regenerative therapies. Although cellular therapy with stem cells and progenitor cells show promise in animal models with short-term improvement, there are additional regenerative approaches that can augment or replace cellular therapies for anal sphincter injuries. The purpose of this article is to review the current knowledge of cellular therapies for anal sphincter injuries and discusses the use of other regenerative therapies including cytokine therapy with CXCL12.
Methods
A literature search was performed to search for articles on cellular therapy and cytokine therapy for anal sphincter injuries and anal incontinence.
Results
The article search identified 337 articles from which 33 articles were included. An additional 12 referenced articles were included as well as 23 articles providing background information. Cellular therapy has shown positive results for treating anal sphincter injuries and anal incontinence in vitro and in one clinical trial. However, cellular therapy has disadvantages such as the source and processing of stem cells and progenitor cells. CXCL12 does not have such issues while showing promising in vitro results for treating anal sphincter injuries. Additionally, electrical stimulation and extracorporeal shock wave therapy are potential regenerative medicine adjuncts for anal sphincter injuries. A vision for future research and clinical applications of regenerative medicine for anal sphincter deficiencies is provided.
Conclusion
There are viable regenerative medicine therapies for anal sphincter injuries beyond cellular therapy. CXCL12 shows promise as a focus of therapeutic research in this field.
Similar content being viewed by others
Abbreviations
- OASI:
-
obstetrical anal sphincter injury
- SDF-1:
-
stromal-derived factor 1
- IM:
-
intramuscular
- IV:
-
intravenous
- GFP:
-
green fluorescent protein
- ISD:
-
intrinsic sphincter deficiency
- ESWT:
-
extracorporeal shock wave therapy
References
Macmillan AK, et al. The prevalence of fecal incontinence in community-dwelling adults: a systematic review of the literature. Dis Colon Rectum. 2004;47(8):1341–9.
Bharucha AE, et al. Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology. 2005;129(1):42–9.
Harvey MA, et al. Obstetrical anal sphincter injuries (OASIS): prevention, recognition, and repair. J Obstet Gynaecol Can. 2015;37(12):1131–48.
Snooks SJ, Henry MM, Swash M. Faecal incontinence due to external anal sphincter division in childbirth is associated with damage to the innervation of the pelvic floor musculature: a double pathology. Br J Obstet Gynaecol. 1985;92(8):824–8.
Allen RE, et al. Pelvic floor damage and childbirth: a neurophysiological study. Br J Obstet Gynaecol. 1990;97(9):770–9.
Sandridge DA, et al. Vaginal delivery is associated with occult disruption of the anal sphincter mechanism. Am J Perinatol. 1997;14(9):527–33.
Crawford LA, et al. Incontinence following rupture of the anal sphincter during delivery. Obstet Gynecol. 1993;82(4 Pt 1):527–31.
Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;6:CD002116.
Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;7:CD001757.
Graf W, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet. 2011;377(9770):997–1003.
Wexner SD, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010;251(3):441–9.
Lam TJ, et al. Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with faecal incontinence: 3 years follow-up. Int J Color Dis. 2014;29(6):755–61.
Majka M, et al. Concise review: mesenchymal stem cells in cardiovascular regeneration: emerging research directions and clinical applications. Stem Cells Transl Med. 2017;6(10):1859–67.
Bitar KN, Zakhem E. Bioengineering the gut: future prospects of regenerative medicine. Nat Rev Gastroenterol Hepatol. 2016;13(9):543–56.
Williams JK, et al. Regenerative medicine therapies for stress urinary incontinence. J Urol. 2016;196(6):1619–26.
Sun L, et al. Electrical stimulation followed by mesenchymal stem cells improves anal sphincter anatomy and function in a rat model at a time remote from injury. Dis Colon Rectum. 2016;59(5):434–42.
Fitzwater JL, et al. Effect of myogenic stem cells on the integrity and histomorphology of repaired transected external anal sphincter. Int Urogynecol J. 2015;26(2):251–6.
Lorenzi B, et al. Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells. Dis Colon Rectum. 2008;51(4):411–20.
Montoya TI, et al. Myogenic stem cell-laden hydrogel scaffold in wound healing of the disrupted external anal sphincter. Int Urogynecol J. 2015;26(6):893–904.
White AB, et al. Effect of myogenic stem cells on contractile properties of the repaired and unrepaired transected external anal sphincter in an animal model. Obstet Gynecol. 2010;115(4):815–23.
Cruz M, et al. Pelvic organ distribution of mesenchymal stem cells injected intravenously after simulated childbirth injury in female rats. Obstet Gynecol Int. 2012;2012:612946.
Pathi SD, et al. Recovery of the injured external anal sphincter after injection of local or intravenous mesenchymal stem cells. Obstet Gynecol. 2012;119(1):134–44.
Salcedo L, et al. Mesenchymal stem cells can improve anal pressures after anal sphincter injury. Stem Cell Res. 2013;10(1):95–102.
Salcedo L, et al. Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells. Stem Cells Transl Med. 2014;3(6):760–7.
Salcedo L, et al. Chemokine upregulation in response to anal sphincter and pudendal nerve injury: potential signals for stem cell homing. Int J Color Dis. 2011;26(12):1577–81.
Lane FL, et al. In vivo recovery of the injured anal sphincter after repair and injection of myogenic stem cells: an experimental model. Dis Colon Rectum. 2013;56(11):1290–7.
Aghaee-Afshar M, et al. Potential of human umbilical cord matrix and rabbit bone marrow-derived mesenchymal stem cells in repair of surgically incised rabbit external anal sphincter. Dis Colon Rectum. 2009;52(10):1753–61.
Kajbafzadeh AM, et al. Functional external anal sphincter reconstruction for treatment of anal incontinence using muscle progenitor cell auto grafting. Dis Colon Rectum. 2010;53(10):1415–21.
Oh HK, et al. Functional and histological evidence for the targeted therapy using biocompatible polycaprolactone beads and autologous myoblasts in a dog model of fecal incontinence. Dis Colon Rectum. 2015;58(5):517–25.
Frudinger A, et al. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up. Gut. 2010;59(1):55–61.
Frudinger A, et al. Autologous skeletal-muscle-derived cell injection for anal incontinence due to obstetric trauma: a 5-year follow-up of an initial study of 10 patients. Color Dis. 2015;17(9):794–801.
Gras S, Tolstrup CK, Lose G. Regenerative medicine provides alternative strategies for the treatment of anal incontinence. Int Urogynecol J. 2017;28(3):341–50.
Cottler-Fox MH, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program. 2003;2003:419–37.
Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30(9):973–81.
Zhou S, et al. Stem cell therapy for treatment of stress urinary incontinence: the current status and challenges. Stem Cells Int. 2016;2016:7060975.
Williams JK, et al. Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency. Stem Cell Res Ther. 2016;7(1):147.
Williams JK, et al. Cell versus chemokine therapy in a nonhuman primate model of chronic intrinsic urinary sphincter deficiency. J Urol. 2016;196(6):1809–15.
Sun L, et al. Regenerating the anal sphincter: cytokines, stem cells, or both? Dis Colon Rectum. 2017;60(4):416–25.
Koudy Williams J, et al. Efficacy and initial safety profile of CXCL12 treatment in a rodent model of urinary sphincter deficiency. Stem Cells Transl Med. 2017;6(8):1740–6.
Deng K, et al. Mesenchymal stem cells and their secretome partially restore nerve and urethral function in a dual muscle and nerve injury stress urinary incontinence model. Am J Physiol Renal Physiol. 2015;308(2):F92–F100.
Kang SB, et al. Sphincter contractility after muscle-derived stem cells autograft into the cryoinjured anal sphincters of rats. Dis Colon Rectum. 2008;51(9):1367–73.
Aref-Adib M, et al. Stem cell therapy for stress urinary incontinence: a systematic review in human subjects. Arch Gynecol Obstet. 2013;288(6):1213–21.
Hijaz AK, et al. Stem cell homing factor, CCL7, expression in mouse models of stress urinary incontinence. Female Pelvic Med Reconstr Surg. 2013;19(6):356–61.
Lenis AT, et al. Impact of parturition on chemokine homing factor expression in the vaginal distention model of stress urinary incontinence. J Urol. 2013;189(4):1588–94.
Couri BM, et al. Effect of pregnancy and delivery on cytokine expression in a mouse model of pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2017;23(6):449–56.
Chatterjee M, Gawaz M. Platelet-derived CXCL12 (SDF-1alpha): basic mechanisms and clinical implications. J Thromb Haemost. 2013;11(11):1954–67.
Duda DG, et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011;17(8):2074–80.
Wurth R, et al. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci. 2014;8:144.
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–31.
Pawig L, et al. Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives. Front Immunol. 2015;6:429.
Scala S. Molecular pathways: targeting the CXCR4-CXCL12 Axis--untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21(19):4278–85.
Peled A, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283(5403):845–8.
Aiuti A, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185(1):111–20.
Peled A, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95(11):3289–96.
MacArthur JW Jr, et al. Mathematically engineered stromal cell-derived factor-1alpha stem cell cytokine analog enhances mechanical properties of infarcted myocardium. J Thorac Cardiovasc Surg. 2013;145(1):278–84.
Penn MS, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res. 2013;112(5):816–25.
Kuraitis D, et al. A stromal cell-derived factor-1 releasing matrix enhances the progenitor cell response and blood vessel growth in ischaemic skeletal muscle. Eur Cell Mater. 2011;22:109–23.
Balog BM, et al. Electrical stimulation for neuroregeneration in urology: a new therapeutic paradigm. Curr Opin Urol. 2019;29(4):458–65.
Jiang HH, et al. Electrical stimulation of the pudendal nerve promotes neuroregeneration and functional recovery from stress urinary incontinence in a rat model. Am J Physiol Renal Physiol. 2018;315(6):F1555–64.
Salcedo L, et al. Low current electrical stimulation upregulates cytokine expression in the anal sphincter. Int J Color Dis. 2012;27(2):221–5.
Romeo P, et al. Extracorporeal shock wave therapy in musculoskeletal disorders: a review. Med Princ Pract. 2014;23(1):7–13.
Fukumoto Y, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis. 2006;17(1):63–70.
Lu Z, et al. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71(2):223–33.
Lin G, et al. In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy. J Sex Med. 2017;14(4):493–501.
Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018;7(9):676–85.
Berkowitz AL, et al. Glioproliferative lesion of the spinal cord as a complication of "stem-cell tourism". N Engl J Med. 2016;375(2):196–8.
Amariglio N, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029.
Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683–92.
Ott HC, McCue J, Taylor DA. Cell-based cardiovascular repair--the hurdles and the opportunities. Basic Res Cardiol. 2005;100(6):504–17.
Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37(11):921–43.
Song M, et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide ac-SDKP. Biomaterials. 2014;35(8):2436–45.
Liu H, et al. CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells. Wound Repair Regen. 2017;25(4):652–64.
Shafiq M, Kong D, Kim SH. SDF-1alpha peptide tethered polyester facilitates tissue repair by endogenous cell mobilization and recruitment. J Biomed Mater Res A. 2017;105(10):2670–84.
Bromage DI, Davidson SM, Yellon DM. Stromal derived factor 1alpha: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther. 2014;143(3):305–15.
Kanki S, et al. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ Heart Fail. 2011;4(4):509–18.
Kowalski K, et al. Stromal derived factor-1 and granulocyte-colony stimulating factor treatment improves regeneration of Pax7−/− mice skeletal muscles. J Cachexia Sarcopenia Muscle. 2016;7(4):483–96.
Acknowledgements
Janine Tillett MSLS AHIP from the Wake Forest School of Medicine Carpenter Library was instrumental in performing the academic article searches for this article.
Author information
Authors and Affiliations
Contributions
Andre Plair: Protocol/project development, data collection, manuscript writing.
Julie Bennington: Manuscript editing.
James Koudy Williams: Manuscript editing.
Candace Parker-Autry: Manuscript editing.
Catherine Ann Matthews: Protocol/project development, manuscript editing.
Gopal Badlani: Protocol/project development, manuscript editing.
Corresponding author
Ethics declarations
Conflict of interest
Andre Plair, grant support from Neomedic.
Julie Bennington, supported by NIH Post-doctoral T32 Institutional Training Grant “Laboratory Animal and Comparative Medicine Research” (NIH T32 OD010957).
James Koudy Williams, None.
Candace Parker-Autry, None.
Catherine Ann Matthews, consultant for Boston Scientific and Pelvalon; grant support from Boston Scientific and Neomedic; expert defense for Johnson and Johnson.
Gopal Badlani, advisory panelist for Olympus and Neotract; board of directors of AAGUS, and Urology Care Foundation.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Plair, A., Bennington, J., Williams, J.K. et al. Regenerative medicine for anal incontinence: a review of regenerative therapies beyond cells. Int Urogynecol J 32, 2337–2347 (2021). https://doi.org/10.1007/s00192-020-04620-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-020-04620-x